Authors’ reply to Schaffalitzky de Muckadell and colleague’s Comment on “Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017”

Detalles Bibliográficos
Autores principales: Ehlken, Birgit, Nathell, Lennart, Gohlke, Annegret, Bocuk, Derya, Toussi, Massoud, Wohlfeil, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475511/
https://www.ncbi.nlm.nih.gov/pubmed/30937851
http://dx.doi.org/10.1007/s40264-019-00815-4
_version_ 1783412760428675072
author Ehlken, Birgit
Nathell, Lennart
Gohlke, Annegret
Bocuk, Derya
Toussi, Massoud
Wohlfeil, Stefan
author_facet Ehlken, Birgit
Nathell, Lennart
Gohlke, Annegret
Bocuk, Derya
Toussi, Massoud
Wohlfeil, Stefan
author_sort Ehlken, Birgit
collection PubMed
description
format Online
Article
Text
id pubmed-6475511
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-64755112019-05-07 Authors’ reply to Schaffalitzky de Muckadell and colleague’s Comment on “Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017” Ehlken, Birgit Nathell, Lennart Gohlke, Annegret Bocuk, Derya Toussi, Massoud Wohlfeil, Stefan Drug Saf Letter to the Editor Springer International Publishing 2019-04-01 2019 /pmc/articles/PMC6475511/ /pubmed/30937851 http://dx.doi.org/10.1007/s40264-019-00815-4 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Letter to the Editor
Ehlken, Birgit
Nathell, Lennart
Gohlke, Annegret
Bocuk, Derya
Toussi, Massoud
Wohlfeil, Stefan
Authors’ reply to Schaffalitzky de Muckadell and colleague’s Comment on “Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017”
title Authors’ reply to Schaffalitzky de Muckadell and colleague’s Comment on “Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017”
title_full Authors’ reply to Schaffalitzky de Muckadell and colleague’s Comment on “Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017”
title_fullStr Authors’ reply to Schaffalitzky de Muckadell and colleague’s Comment on “Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017”
title_full_unstemmed Authors’ reply to Schaffalitzky de Muckadell and colleague’s Comment on “Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017”
title_short Authors’ reply to Schaffalitzky de Muckadell and colleague’s Comment on “Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017”
title_sort authors’ reply to schaffalitzky de muckadell and colleague’s comment on “evaluation of the reported rates of severe hypersensitivity reactions associated with ferric carboxymaltose and iron (iii) isomaltoside 1000 in europe based on data from eudravigilance and vigibase™ between 2014 and 2017”
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475511/
https://www.ncbi.nlm.nih.gov/pubmed/30937851
http://dx.doi.org/10.1007/s40264-019-00815-4
work_keys_str_mv AT ehlkenbirgit authorsreplytoschaffalitzkydemuckadellandcolleaguescommentonevaluationofthereportedratesofseverehypersensitivityreactionsassociatedwithferriccarboxymaltoseandironiiiisomaltoside1000ineuropebasedondatafromeudravigilanceandvigibasebetween2014and2017
AT nathelllennart authorsreplytoschaffalitzkydemuckadellandcolleaguescommentonevaluationofthereportedratesofseverehypersensitivityreactionsassociatedwithferriccarboxymaltoseandironiiiisomaltoside1000ineuropebasedondatafromeudravigilanceandvigibasebetween2014and2017
AT gohlkeannegret authorsreplytoschaffalitzkydemuckadellandcolleaguescommentonevaluationofthereportedratesofseverehypersensitivityreactionsassociatedwithferriccarboxymaltoseandironiiiisomaltoside1000ineuropebasedondatafromeudravigilanceandvigibasebetween2014and2017
AT bocukderya authorsreplytoschaffalitzkydemuckadellandcolleaguescommentonevaluationofthereportedratesofseverehypersensitivityreactionsassociatedwithferriccarboxymaltoseandironiiiisomaltoside1000ineuropebasedondatafromeudravigilanceandvigibasebetween2014and2017
AT toussimassoud authorsreplytoschaffalitzkydemuckadellandcolleaguescommentonevaluationofthereportedratesofseverehypersensitivityreactionsassociatedwithferriccarboxymaltoseandironiiiisomaltoside1000ineuropebasedondatafromeudravigilanceandvigibasebetween2014and2017
AT wohlfeilstefan authorsreplytoschaffalitzkydemuckadellandcolleaguescommentonevaluationofthereportedratesofseverehypersensitivityreactionsassociatedwithferriccarboxymaltoseandironiiiisomaltoside1000ineuropebasedondatafromeudravigilanceandvigibasebetween2014and2017

Ejemplares similares